Q3 2025 Camlin Fine Sciences Ltd Earnings Call Transcript
Key Points
- Camlin Fine Sciences Ltd (BOM:532834) reported a 2% increase in turnover, reaching INR433.49 crore, despite challenging market conditions.
- Gross margins improved from 48% to 50%, indicating better cost management and pricing strategies.
- The Vanillin vertical showed strong performance with increased sales prices and output, driven by potential antidumping actions on Chinese manufacturers.
- The Blends business experienced a 20% growth, particularly in the American continent and India, and is expected to continue growing at this rate.
- The company successfully completed a rights issue with overwhelming response, using the proceeds to repay non-convertible debentures and maintain stable debt levels.
- The company faced volatility in foreign exchange, resulting in some financial hits this quarter.
- Interest costs increased due to foreign currency borrowings and the appreciation of the dollar, impacting financial performance.
- The European operations incurred significant losses, with a reported INR44 crore loss in the first nine months of the year.
- The Vanillin and Guaiacol lines are not expected to break even until they reach 70% utilization, which is projected for FY26.
- The company is still facing challenges in the Chinese market, with losses of INR3 crore to INR4 crore per quarter.
Ladies and gentlemen, good day, and welcome to the Q3 FY25 results conference call of Camlin Fine Science Limited. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Ashish Dandekar, Chairman and Managing Director. Thank you, and over to you, sir.
Thank you. Ladies and gentlemen, welcome to this earnings call. I know you have a busy day ahead, so without much pause, we'll get into the actual workings of the call. Our CFO, Santosh Parab will give you a brief of the highlights, following which he and our MD, Nirmal Momaya, will answer all your questions.
Over to you, Santosh.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
